Brooklyn Immunotherapeuti Current Financial Leverage

BTX
 Stock
  

USD 0.57  0.02  3.64%   

Brooklyn Immunotherapeuti's financial leverage is the degree to which the firm utilizes its fixed-income securities and uses equity to finance projects. Companies with high leverage are usually considered to be at financial risk. Brooklyn Immunotherapeuti's financial risk is the risk to Brooklyn Immunotherapeuti stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Continue to the analysis of Brooklyn Immunotherapeuti Fundamentals Over Time.
  
Refresh
Brooklyn Immunotherapeuti Total Debt is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Total Debt of 2.72 Million in 2021. Debt Current is likely to rise to about 437.2 K in 2022, whereas Issuance Repayment of Debt Securities is likely to drop (966.8 K) in 2022.

Brooklyn Current Financial Burden

Brooklyn Immunotherapeuti's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Brooklyn Immunotherapeuti's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Brooklyn Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Brooklyn Immunotherapeuti's stakeholders.

Asset vs Debt

Equity vs Debt

For most companies, including Brooklyn Immunotherapeuti, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for the executing running Brooklyn Immunotherapeutics the most critical issue when dealing with liquidity needs is whether the current assets are properly aligned with its current liabilities. If not, management will need to obtain alternative financing to ensure that there are always enough cash equivalents on the balance sheet in reserve to pay for obligations.
Given that Brooklyn Immunotherapeuti's debt-to-equity ratio measures a company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Brooklyn Immunotherapeuti is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Brooklyn Immunotherapeuti to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Brooklyn Immunotherapeuti is said to be less leveraged. If creditors hold a majority of Brooklyn Immunotherapeuti's assets, the company is said to be highly leveraged.

Brooklyn Immunotherapeuti Quarterly Debt to Equity Ratio

3.988

Share
Given the importance of Brooklyn Immunotherapeuti's capital structure, the first step in the capital decision process is for the management of Brooklyn Immunotherapeuti to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Brooklyn Immunotherapeutics to issue bonds at a reasonable cost.

Brooklyn Immunotherapeuti Financial Leverage Rating

Brooklyn Immunotherapeutics bond ratings play a critical role in determining how much Brooklyn Immunotherapeuti have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Brooklyn Immunotherapeuti's borrowing costs.
Piotroski F Score
4  Poor
Beneish M Score

Brooklyn Immunotherapeuti Debt to Cash Allocation

As Brooklyn Immunotherapeutics follows its natural business cycle, the capital allocation decisions will not magically go away. Brooklyn Immunotherapeuti's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors. Many companies eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
The company has 2.72 M in debt with debt to equity (D/E) ratio of 0.42, which is OK given its current industry classification. Brooklyn Immunotherapeuti has a current ratio of 5.0, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Brooklyn Immunotherapeuti until it has trouble settling it off, either with new capital or with free cash flow. So, Brooklyn Immunotherapeuti's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Brooklyn Immunotherapeuti sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Brooklyn to invest in growth at high rates of return. When we think about Brooklyn Immunotherapeuti's use of debt, we should always consider it together with cash and equity.

Brooklyn Immunotherapeuti Inventories Over Time

Brooklyn Immunotherapeuti Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Brooklyn Immunotherapeuti uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Brooklyn Immunotherapeuti Debt Ratio

    
  14.1   
It appears most of the Brooklyn Immunotherapeuti's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Brooklyn Immunotherapeuti's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Brooklyn Immunotherapeuti, which in turn will lower the firm's financial flexibility. Like all other financial ratios, a Brooklyn Immunotherapeuti debt ratio should be compared their industry average or other competing firms.
Share Download
Share Download

Brooklyn Immunotherapeuti Historical Liabilities

While analyzing the current debt level is an essential aspect of forecasting the current year budgeting needs of Brooklyn Immunotherapeuti, understanding its historical liability is critical in projecting Brooklyn Immunotherapeuti's future earnings, especially during periods of low and high inflation and deflation. Many analysts look at the trend in assets and liabilities and evaluate how Brooklyn Immunotherapeuti uses its financing power over time.
In order to fund their growth, businesses such as Brooklyn Immunotherapeuti widely use Financial Leverage. For most companies, financial capital is raised by issuing debt securities and by selling common stock. The debt and equity that make up Brooklyn Immunotherapeuti's capital structure have many risks and return implications. Leverage is an investment strategy of using borrowed money to increase the potential return of an investment. Please note, the concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Understaning Brooklyn Immunotherapeuti Use of Financial Leverage

Brooklyn Immunotherapeuti financial leverage ratio helps in determining the effect of debt on the overall profitability of the company. It measures Brooklyn Immunotherapeuti's total debt position, including all of outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Brooklyn Immunotherapeuti assets, the company is considered highly leveraged. Understanding the composition and structure of overall Brooklyn Immunotherapeuti debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business and if it is worth investing in it.
Last ReportedProjected for 2022
Total Debt2.7 M3.8 M
Debt Current426 K437.2 K
Debt Non Current2.3 M2.6 M
Issuance Repayment of Debt Securities-942 K-966.8 K
Long Term Debt to Equity 0.00031  0.000318 
Debt to Equity Ratio 3.99  4.30 
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York. Brooklyn Immunotherapeuti operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. It employs 10 people.
Please read more on our technical analysis page.

Brooklyn Immunotherapeuti Investors Sentiment

The influence of Brooklyn Immunotherapeuti's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Brooklyn. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Brooklyn Immunotherapeuti Implied Volatility

    
  35.99  
Brooklyn Immunotherapeuti's implied volatility exposes the market's sentiment of Brooklyn Immunotherapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Brooklyn Immunotherapeuti's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Brooklyn Immunotherapeuti stock will not fluctuate a lot when Brooklyn Immunotherapeuti's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Brooklyn Immunotherapeuti in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Brooklyn Immunotherapeuti's short interest history, or implied volatility extrapolated from Brooklyn Immunotherapeuti options trading.

Current Sentiment - BTX

Brooklyn Immunotherapeuti Investor Sentiment

Greater number of Macroaxis users are currently bullish on Brooklyn Immunotherapeutics. What is your opinion about investing in Brooklyn Immunotherapeutics? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Pair Trading with Brooklyn Immunotherapeuti

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brooklyn Immunotherapeuti position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brooklyn Immunotherapeuti will appreciate offsetting losses from the drop in the long position's value.

Brooklyn Immunotherapeuti Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Brooklyn Immunotherapeuti could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Brooklyn Immunotherapeuti when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brooklyn Immunotherapeuti - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brooklyn Immunotherapeutics to buy it.
The correlation of Brooklyn Immunotherapeuti is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brooklyn Immunotherapeuti moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brooklyn Immunotherapeuti moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brooklyn Immunotherapeuti can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of Brooklyn Immunotherapeuti Fundamentals Over Time. Note that the Brooklyn Immunotherapeuti information on this page should be used as a complementary analysis to other Brooklyn Immunotherapeuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for Brooklyn Stock analysis

When running Brooklyn Immunotherapeuti price analysis, check to measure Brooklyn Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brooklyn Immunotherapeuti is operating at the current time. Most of Brooklyn Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Brooklyn Immunotherapeuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brooklyn Immunotherapeuti's price. Additionally, you may evaluate how the addition of Brooklyn Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
CEO Directory
Screen CEOs from public companies around the world
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Is Brooklyn Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brooklyn Immunotherapeuti. If investors know Brooklyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brooklyn Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Brooklyn Immunotherapeuti is measured differently than its book value, which is the value of Brooklyn that is recorded on the company's balance sheet. Investors also form their own opinion of Brooklyn Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Brooklyn Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brooklyn Immunotherapeuti's market value can be influenced by many factors that don't directly affect Brooklyn Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brooklyn Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Brooklyn Immunotherapeuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brooklyn Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.